Immunovant Inc.

17.13
-1.24 (-6.75%)
At close: Mar 31, 2025, 3:59 PM
17.09
-0.20%
After-hours: Mar 31, 2025, 04:36 PM EDT

Immunovant Income Statement

Year FY24 FY23 FY22 FY21 FY20 FY19 FY18
Revenue n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue 231K 1.32M 1.23M 998K 21K n/a n/a
Gross Profit -231K -1.32M -1.23M -998K -21K n/a n/a
Operating Income -282.71M -198.47M -156.16M -107.79M -65.67M -450 -136.74M
Interest Income 24.95M 7.58M n/a n/a 625.00 n/a n/a
Pretax Income -258.77M -210.95M -156.81M -107.79M -66.29M -448 -136.74M
Net Income -259.34M -210.96M -156.73M -107.43M -66.39M -448 -136.74M
Selling & General & Admin 57.28M 48.02M 54.23M 39.51M 18.15M 448.00 1.48M
Research & Development 212.93M 160.26M 101.81M 68.6M 47.93M 25.73M 135.26M
Other Expenses 12.5M -253K -781K 328K 412K n/a n/a
Operating Expenses 282.71M 208.28M 156.03M 108.12M 66.08M 448.00 136.74M
Interest Expense n/a 12.48M 655K n/a 625K n/a n/a
Selling & Marketing Expenses n/a n/a n/a n/a n/a -2.69M n/a
Cost & Expenses 282.71M 208.28M 156.03M 108.12M 66.08M 448.00 136.74M
Income Tax 567K 9K -84K -358K 97K 19K n/a
Shares Outstanding (Basic) 138.1M 123.08M 109.68M 87.76M 43.2M 14.38M 10M
Shares Outstanding (Diluted) 138.1M 123.08M 109.68M 87.76M 43.2M 14.38M 10M
EPS (Basic) -1.88 -1.71 -1.43 -1.22 -1.54 n/a -13.68
EPS (Diluted) -1.88 -1.71 -1.43 -1.22 -1.54 n/a -13.67
EBITDA -269.98M -209.63M -155.58M -106.79M -65.64M -28.41M n/a
Depreciation & Amortization 231K 1.32M 1.23M 998K 21K 10K 136.74M